SecBot SecBot
Insider Cluster (7 insiders) ·Filed Nov 12, 2026

LRMR

Larimar Therapeutics, Inc.
BULLISH
Impact 4/10
Horizonweeks Processed3d 18h ago
Insider cluster: 3 insiders, $0.1M total
Actionable Insight ▲ Bullish

Insider buying after a BLA submission is a positive signal, but the dollar amounts are modest relative to market cap. Watch for FDA acceptance of the BLA and any PDUFA date announcement as the next catalyst.

DirectionBullish
Confidencemedium
Horizonweeks

nomlabofusp

● Neutral Named in this insider cluster
Impact
Phase
Filed/rolling BLA submission
Time to market
If the BLA submission is completed by end of 2026 and accepted by the FDA, a PDUFA decision on accelerated approval could come in mid-to-late 2027. A confirmatory Phase 3 trial would still be required for full approval.
Next catalyst
None dated

What to watchWatch for completion of the rolling BLA submission (remaining modules expected by end of 2026) and the FDA's subsequent acceptance for filing, which would trigger a PDUFA date assignment. The ICAR 2026 poster presentations on November 12 may provide incremental OLE data but are unlikely to be a major stock-moving event since the data is previously disclosed. The key binary catalyst remains the FDA's accelerated approval decision, likely in 2027.

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+1
Entry
$3.02
T+0 close · Nov 12, 2026 · via day close
Latest settled
−0.66%
T+1 · $3.00
Vs SPY
+1.25%
α at T+1
Next horizon
T+5
in 3d
  1. T+0 · Nov 13 $3.02entry
  2. T+1 · 20h ago −0.66%α +1.25% · $3.00
  3. T+5 · in 3d Pending
  4. T+20 · in 27d Pending
  5. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Multiple Larimar Therapeutics insiders, including the CEO, CFO, President/COO, and directors, made open-market purchases totaling approximately $382K in the week following the company's BLA submission for nomlabofusp. The cluster represents about 0.13% of market cap, a modest but notable signal of insider confidence after a major regulatory milestone.

Key Financial Metrics

Direction
buying
Total Value
$382.0K
Insiders
7

Key Facts

  • Seven insiders purchased shares in a 7-day window (Nov 11-12, 2026)
  • Total open-market purchases: ~$382K across all seven insiders
  • CEO Carole Ben-Maimon purchased $50K worth of shares
  • CFO Michael Celano purchased $50K worth of shares
  • President/COO John Harlow Jr. purchased $50K worth of shares
  • Director Thomas Hamilton purchased $187K worth of shares (largest single trade)
  • Purchases followed the company's BLA submission for nomlabofusp (Friedreich's ataxia) on Nov 9, 2026
  • Company had $128.7M cash as of Sep 30, 2026, with runway into late Q2 2027
  • Cluster represents ~0.13% of $284M market cap

Financial Impact

Total insider purchases of ~$382K, or 0.13% of market cap

Risk Factors

  • Insider purchases are small relative to market cap (0.13%) and may not indicate strong conviction
  • BLA submission does not guarantee FDA acceptance or approval
  • Cash burn rate is high ($71.7M in 6 months); runway only into late Q2 2027
  • Clinical-stage biotech with no approved products carries inherent regulatory and commercial risk

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
94% bullish (17 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-LRMR-1794524451153

Track record

13 reports on LRMR

Performance horizon

1 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +36.13% at T+20 after the Sep 22, 2026 report. 3 of 5 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 4/10 Entry $3.00 Now $3.00 0.00% settles Feb 12
  2. Nov 16, 2026today Press Release Bullish 7/10 Entry $3.10 Now $3.00 −3.23% settles Feb 12
  3. Nov 12, 20264d ago Insider Cluster Bullish 4/10 Viewing Entry $3.02 Now $3.00 −0.66% settles Feb 11
  4. Nov 9, 20267d ago 8-K Bullish 7/10 Entry $2.69 Now $3.00 +11.52% settles Feb 8
  5. Nov 5, 202611d ago Press Release Neutral 2/10 Entry $2.39 Now $3.00 +25.52% settles Feb 4
  6. Sep 29, 20266w ago Press Release Neutral 3/10 Entry $3.20 Now $3.00 −6.10% settles Dec 24
  7. Sep 22, 20267w ago Institutional Cluster Bearish 4/10 Entry $3.82 Now $3.00 +21.47% settles Dec 16
  8. May 14, 202626w ago 8-K Bullish 7/10 No price data
  9. May 14, 202626w ago Press Release Bullish 7/10 Entry $3.89 to $4.01 Now $3.00 −22.88% ▲ +3.08% −0.50% vs SPY
  10. Mar 19, 202634w ago Press Release Mixed 7/10 Entry $4.47 to $3.59 Now $3.00 −32.89% ▼ −19.69% −34.03% vs SPY
Showing 10 of 13

US Market Status

Market Closed · Opens in 6h 41m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 13, 2026